Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Total Non-current Liabilities
All obligations due after more than one year.
Monopar Therapeutics Inc.NASDAQ: MNPR
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $131.57K, compared with $0 a year earlier. Over 3 fiscal years it compounded at +164.1% a year.
Context
- Total non-current liabilities amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 154.92K USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 154.92K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 8.41K | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Total non-current liabilities amounts to 0.1% of total assets for MNPR, versus a peer median of 13.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $756.7M USD | +2052.0% | -16.0% | 64.3% | |
| Mar 2026 | $440.25M USD | -2.8% | +10.0% | 151.0% | |
| Jun 2026 | $139.87M USD | -14.2% | +37.9% | 19.3% | |
| Mar 2026 | $100.74M USD | +11.9% | +16.9% | 46.2% | |
| Mar 2026 | $49.19M USD | -42.8% | -16.3% | 7.5% | |
| Dec 2025 | €47.75M EUR | -31.0% | -24.8% | 76.2% | |
| Sep 2026 | $10.26M USD | +155.6% | +296.2% | 2.0% | |
| Mar 2026 | $8.42M USD | +34.2% | +68.7% | 4.1% | |
| Mar 2026 | $6.8M USD | -50.9% | -16.7% | 3.8% | |
| Jun 2026 | $595K USD | -98.3% | -1.0% | 1.5% | |
| Mar 2026 | $131.57K USD | — | +164.1% | 0.1% | |
| Peer median (excluding MNPR) | — | -8.5% | +4.5% | 13.4% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.